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Introduction
Early generation drug-eluting stents (DES), releasing Sirolimus or 
Paclitaxel, have reduced the occurrence of restenosis and the need 
for repeat revascularization, compared with bare metal stents 
(BMS).
1-4) Stent thrombosis can be exaggerated by basic DES prop-
erties that inhibit intimal regeneration and healing processes. There 
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has been concern about the use of DES in highly thrombogenic situ-
ations, such as acute myocardial infarction (AMI). However, based 
on the favorable results of clinical studies, DES have been widely used 
in more complex clinical and anatomic situations, including AMI.
5-7)
Two early generation DES: the Sirolimus-eluting stent (SES) (Cor-
dis, Johnson and Johnson, Miami Lakes, FL, USA) and the Paclitaxel-
eluting stent (PES) (Boston Scientific, Natick, MA, USA) have revealed 267 Gye-Sik Min, et al.
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improvements in clinical and angiographic outcomes in the treat-
ment of many coronary lesions, compared with BMS.
2-4) However, 
to date there is limited long term clinical data directly comparing 
outcomes of SES with PES implantation, in the treatment of AMI 
patients. In this retrospective study we compared four-year clinical 
outcomes of SES versus PES implantation in patients with AMI. 
Subjects and Methods
Study patients
From January 2004 to August 2006, we evaluated all ST-segment 
elevation myocardial infarction (STEMI) and non-ST segment eleva-
tion myocardial infarction (NSTEMI) patients who had been treated 
with either SES or PES implantation, at the Chungnam National 
University Hospital. They were retrospectively analyzed for four years 
after the index percutaneous coronary intervention (PCI). 
 
Treatment methods
All patients were treated according to standardized guidelines.
8) 
Patients with acute STEMI all underwent a primary PCI. The infarct-
related lesions were assessed by electrocardiogram, echocardio-
gram and coronary angiogram by the attending physician. All pro-
cedures were performed according to standard techniques, and 
the final interventional strategy was left to the discretion of the 
operators. The culprit lesions were fully covered with a single or 
multiple stents. Direct implantation of a stent without prior balloon 
dilatation was also allowed. Adjunctive balloon dilatation within 
the stent was performed where necessary. The final inflation was 
performed using either a stent balloon or another short balloon wi-
thin the stent. Intervention in non-infarct-related arteries during the 
initial procedure was discouraged, especially in STEMI patients. The 
removal of thrombi by aspiration catheter was performed at the 
operator’s discretion. Glycoprotein IIb/IIIa receptor antagonists were 
selectively used according to the operator’s judgment.
Study methods
We included consecutive patients with AMI who underwent PCI. 
We collected initial and follow-up clinical outcomes from their me-
dical records and analyzed angiographic findings. Of the patients 
lost-to-follow-up, clinical data were acquired by means of tele-
phone interview. The occurrences and causes of death were assessed 
by the medical records of our own or from other clinics, telephone in-
terview, or from the data of Statistics Korea. 
Quantitative coronary angiography 
The coronary angiographies were performed after administra-
tion of intracoronary nitroglycerin, when possible. Quantitative cor-
onary analysis was performed by an experienced investigator, who 
was not aware of treatment assignment, using the guiding catheter 
for magnification calibration with an automated edge-detection sys-
tem (CAAS V, Pie Medical Imaging). The quantitative measurements 
included: reference diameter; lesion length; and the minimal luminal 
diameter before the procedure, after the procedure and at follow-
up. The in-segment or target lesion was defined as the in-stent 
segment plus the adjacent proximal and distal 5 mm segments. 
The in-segment minimal lumen diameter was determined both af-
ter the procedure and at follow-up. An acute gain was defined as 
a change in minimal luminal diameter between pre- and post-in-
tervention measurements. A late loss was defined as a change in 
minimal luminal diameter between post-intervention and follow-
up. A recurrent restenosis was defined as an in-segment diameter 
stenosis ≥50% according to follow-up angiography. 
Definition of clinical event
Procedural success was defined as no laboratory death, no em-
ergency bypass surgery, and thrombolysis in myocardial infarction 
(TIMI) grade 2 flow in the distal part of the infarct related artery with 
a residual stenosis less than 30%. Reinfarction was diagnosed based 
on recurrent symptoms and/or new electrocardiographic changes 
in association with a re-elevation of creatine kinase-MB levels >1.5 
times the previous value if within 48 hours, or >3 times the upper 
normal limit if longer than 48 hours from the index infarction. We 
applied the Academic Research Consortium definitions for stent 
thrombosis.
9) With respect to timing, stent thrombosis is classified 
as acute, subacute, late, and very late. By the level of certainty, it is 
defined as definite, probable, or possible. Definite and probable stent 
thromboses were included in major adverse cardiac events (MACE). 
A target lesion revascularization (TLR) was considered if the target 
lesion stenosis was at least 50% of the diameter, in the presence 
of ischemic signs or symptoms or when target lesion stenosis was at 
least 70%. A TLR was defined as a repeat intervention or bypass sur-
gery of the target lesion owing to restenosis or reocclusion of the 
target lesion. 
A target vessel revascularization (TVR) was defined as a repeat 
revascularization of an infarct-related artery. The occurrence of 
MACE including death, reinfarction, stent thrombosis (definite and 
probable), and TVR at 48 months were evaluated. Death from car-
diac causes included: death from recurrent myocardial infarction, 
cardiac perforation, pericardial tamponade, arrhythmia or conduc-
tion abnormality, complications of the index procedure, and heart 
failure or stroke during follow-up. All deaths that could not be clearly 
attributed to a non-cardiac cause were also considered to be car-
diac deaths. 268  Sirolimus- vs. Paclitaxel-Eluting Stents for AMI
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Statistical analysis
Data are expressed as mean±SD or median (range) for continu-
ous variables and as frequencies (percentages) for the categorical 
variables. Differences between groups were assessed using Chi-
square (χ2) or Fisher’s exact tests for categorical variables, and un-
paired t-tests or Mann-Whitney U tests for continuous variables. 
The relative risk and its 95% confidence interval (CI) were computed 
for outcome measures. Event-free survival (events: death, reinfarc-
tion, TVR, stent thrombosis and MACE) during four years was ana-
lyzed using the Kaplan-Meier method, and the differences between 
groups were assessed by a log-rank test. 
Multivariate analyses involved a backwards elimination tech-
nique, variables with a p of <0.20 and clinically relevant predictors 
were used in the final model. All p of were two-sided and a proba-
bility value of p<0.05 was considered significant. Statistical analy-
sis was performed using commercially available software {Statistical 
Package for the Social Sciences (SPSS) 17.0 for Windows, SPSS Inc., 
Chicago, IL, USA}. 
Results
From January 2004 to August 2006, a total of 668 AMI patients 
were admitted at the Chungnam National University Hospital. Of 
them, 176 patients were excluded from this study; 59 patients were 
treated with balloon angioplasty alone, 25 were treated with BMS 
implantation and two with other types of DES, 27 patients deferr-
ed from angioplasty, eleven were treated with bypass surgery, nine 
were diagnosed with variant angina, five were treated with thrombi 
suction alone, and eight could not be recanalized due to poor gen-
eral condition. Finally, 522 patients treated with either SES (n=299, 
57.3%) or PES (n=223, 46.7%) implantation were included in this 
study (Fig. 1).
Baseline clinical characteristics
Baseline clinical characteristics are shown in Table 1. Mean age 
(63±12 years) and sex distribution were identical for both groups. 
The proportion of STEMI was significantly lower in the SES popula-
tion compared to the PES population (59% vs. 71%, p<0.001). The 
risk factors for ischemic heart disease, underlying heart disease, and 
the frequency of arrhythmia were equal in both groups. The left ven-
tricular ejection fraction of 51% was also equal in the two groups. 
Fig. 1. Study population. STEMI: ST-elevation myocardial infarction, NSTE-
MI: non-ST elevation myocardial infarction, BMS: bare-metal stent, DES: 
drug-eluting stent, PCI: percutaneous coronary intervention, SES: Sirolim-
us-eluting stent, PES: Paclitaxel-eluting stent.
All acute STEMI/NSTEMI patients
(January 2004-August 2006, n=668)
N=522
N=146
Excluded
SES (n=299)
STEMI (n=176)
NSTEMI (n=123)
PES (n=223)
STEMI (n=168)
NSTEMI (n=65)
Balloon angioplasty (59)
BMS (25)
Other DES (2)
Medical treatment (27)
Bypass surgery (11)
Variant angina (9)
Suction or thrombolysis (5)
Failed PCI (8)
Table 1. Baseline clinical characteristics
SES
(n=299)
PES
(n=223)
p
Age (years) 63±12 63±13 0.52
Sex (M/F) 209/90 158/65 0.85
Type of AMI, n (%)
STEMI 176 (59) 158 (71) 0.006
NSTEMI 123 (41) 65 (29)
Risk factors, n (%)
Hypertension 144 (48) 103 (42) 0.66
Diabetes 82 (27) 60 (27) 0.92
Smoking 171 (57) 121 (54) 0.53
T-cholesterol >200 mg/dL 84 (29) 54 (26) 0.48
Family history 16 (5) 10 (5) 0.69
Previous PCI, n (%) 15 (5) 13 (6) 0.70
Previous MI, n (%) 18 (6) 9 (4) 0.43
Previous CABG, n (%) 2 (1) 0 (0) 0.24
Preinfarction angina, n (%) 75 (25) 50 (23) 0.53
LVEF (%) 51±12  51±11  0.77 
VT/V-fib, n (%) 15 (5) 14 (6) 0.54
Atrial fibrillation, n (%) 8 (3) 4 (2) 0.38
Complete AV block, n (%) 25 (8) 25 (11)  0.30 
SES: Sirolimus-eluting stent, PES: Paclitaxel-eluting stent, AMI: acute myo-
cardial infarction, NSTEMI: non-ST elevation myocardial infarction, STEMI: 
ST-elevation myocardial infarction, PCI: percutaneous coronary interven-
tion, CABG: coronary artery bypass graft, LVEF: left ventricular ejection 
fraction, VT: ventricular tachycardia, V-fib: ventricular fibrillation, AV: atrio-
ventricular
Table 2. Procedural data including pain-to-ER time and door-to-balloon 
time for patients with acute myocardial infarction
SES
(n=299)
PES
(n=223)
p
STEMI/NSTEMI 176/123 168/65
STEMI (minutes)
Pain-to-ER time 19-1380 (208) 30-1715 (180) 0.99
Door-to-Balloon time 20-1818 (68) 15-1690 (67) 0.31
NSTEMI (hours)
Pain-to-ER time 0.3-480 (10) 0.2-168 (11) 0.55
Door-to-Balloon time 0.5-187 (15) 0.6-232 (14) 0.21
SES: Sirolimus-eluting stent, PES: Paclitaxel-eluting stent, STEMI: ST-eleva-
tion myocardial infarction, NSTEMI: non-ST elevation myocardial infarction, 
ER: emergency room269 Gye-Sik Min, et al.
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Reperfusion time
The durations from symptom onset to emergency room (ER) ar-
rival (pain-to-ER time) and from ER arrival to reperfusion (door-to-
balloon time) are shown in Table 2. The median of pain-to-ER time 
was about 3 hours in STEMI and about 10 hours in NSTEMI patients. 
The median of door-to-balloon time was less than 70 minutes in 
STEMI and about 15 hours in NSTEMI patients. Pain-to-ER and door-
to-balloon times were the same for the two groups.
Coronary angiographic findings
Coronary angiographic findings are shown in Table 3. Angiogra-
phic diagnoses and lesion types were the same between the two 
groups. In the SES group, the incidence of the infarct-related artery 
being the right coronary artery was significantly lower than the PES 
group (31% vs. 39%, p=0.05). A bifurcation lesion was more frequ-
ent in the SES group compared with the PES group (40% vs. 34%, 
p=0.005). The frequency of initial TIMI 0 flow was lower in the SES 
group (47% vs. 58%, p=0.005) and TIMI 3 flow was higher (27% vs. 
16%, p=0.001). There were no significant differences in the presence 
of intraluminal thrombi, proximal tortuosity, lesion angulation, or 
ostial location between the two groups.
Table 3. Coronary angiographic findings
SES
(n=299)
PES
(n=223)
p
No. of diseased vessels, n (%)
1 VD 102 (34) 76 (34) 0.93
2 VD 97 (33) 74 (33) 0.71
3 VD 100 (33) 73 (33) 0.50
LMCA lesion 20 (7) 10 (5) 0.34
Lesion types, n (%)
A 0 (0) 1 (0.4) 0.43
B1 33 (11) 18 (8) 0.30
B2 133 (45) 91 (41) 0.42
C 133 (45) 113 (51) 0.18
Infarct related artery, n (%)
LAD 151 (50) 93 (42) 0.08
RCA 93 (31) 88 (39) 0.05
LCx 50 (17) 42 (19) 0.64
LMCA 5 (2) 0 (0) 0.13
Bifurcation lesion, n (%) 120 (40) 63 (34) 0.005
Two GWs insertion, n (%) 77 (26) 46 (21) 0.18
Kissing balloon, n (%) 64 (21) 35 (16) 0.11
Initial TIMI flow, n (%)
0 139 (47) 130 (58) 0.005
I 27 (9) 31 (14) 0.09
II 51 (17) 26 (12) 0.18
III 82 (27) 36 (16) 0.001
Visible thrombus, n (%) 0.29
None-Mild 175 (58) 119 (53)
Moderate 98 (33) 76 (34)
Heavy 26 (9) 28 (13)
Proximal tortuosity, n (%) 0.45
None-Mild 211 (70) 152 (68)
Moderate 77 (26) 57 (26)
Severe 11 (4) 14 (6)
Lesion angulation, n (%) 0.53
None-Mild 241 (78) 174 (81)
Moderate 55 (18) 48 (22)
Heavy 3 (1) 1 (0.1)
Ostial lesion, n (%) 48 (10) 28 (13) 0.32
SES: Sirolimus-eluting stent, PES: Paclitaxel-eluting stent, 1 VD: one vessel 
disease, 2 VD: two vessel disease, 3 VD: triple vessel disease, LAD: left ante-
rior descending artery, RCA: right coronary artery, LCx: left circumflex ar-
tery, LMCA: left main coronary artery, GW: guidewire, TIMI: Thrombolysis in 
Myocardial Infarction
Table 4. Procedural characteristics
SES
(n=299)
PES
(n=223)
p
Temporary pacemaker, n (%) 13 (4) 19 (9) 0.06
IABP support, n (%) 6 (2) 7 (3) 0.41
Access site, n (%)
Femoral 42 (14) 25 (11) 0.36
Radial 257 (86) 198 (89)
GpIIb/IIIa inhibitor, n (%) 34 (11) 7 (3) 0.13
Thrombus aspiration, n (%) 71 (24) 80 (36) 0.09
Number of stents, n (%) 
1 268 (90) 194 (87) 0.41
≥2 31 (10) 29 (13) 0.41
Stent diameter (mm) 3.28±0.29 3.29±0.30 0.50
Total stent length (mm) 30.7±3.9 30.8±4.4 0.86
Final balloon size (mm) 3.3±0.3 3.3±0.3 0.84
Final balloon pressure (atm) 15.3±3.8 15.1±4.1 0.50
Postdilation, n (%) 118 (40) 86 (39) 0.86
Nonculprit lesion PCI, n (%) 38 (9)    21 (13) 0.27
Post-TIMI flow, n (%)
0 2 (1) 4 (2) 0.66
1 3 (1) 3 (1) 0.66
2 31 (10) 26 (12) 0.23
3 263 (88) 190 (85) 0.12
Procedural success, n (%) 287 (96) 209 (94) 0.17
SES: Sirolimus-eluting stent, PES: Paclitaxel-eluting stent, IABP: intra-aortic 
balloon pump, PCI: percutaneous coronary intervention, TIMI: Thrombolysis 
in Myocardial Infarction270  Sirolimus- vs. Paclitaxel-Eluting Stents for AMI
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Procedural characteristics
Procedural characteristics are shown in Table 4. The frequencies 
of temporary pacemaker back-up, intra-aortic balloon pump support 
and glycoprotein IIb/IIIa inhibitor use were equivalent between the 
two groups. A transradial approach was performed in more than 
85% of cases in both groups. Aspiration of thrombi using a suction 
catheter was performed in 24% of cases in the SES and 36% in the 
PES group (p=0.09). The majority of patients were treated with 
single stent implantation (90% in SES vs. 87% in PES, p=0.41). The 
length and the diameter of deployed stents were similar between 
the two groups. As were the size, length and the maximal inflation 
pressure of the final balloon used. Non-culprit lesion intervention 
was performed in 9% of the SES and 13% of the PES group (p=0.27). 
The distribution of post-procedural TIMI flow and the procedural 
success rate were also similar. 
Four-year clinical outcomes in ST-segment elevation 
myocardial infarction patients (n=334)
The occurrences of death (total and cardiac), recurrent infarction, 
stent thrombosis, TVR, and MACE (composite of death, re-infarction, 
stent thrombosis, and TVR) were the same between the SES and 
PES treated groups in 344 STEMI patients (Fig. 2). 
Four-year clinical outcomes in non-ST segment elevation 
myocardial infarction patients (n=188)
The occurrences of death (total and cardiac), recurrent infarction, 
Fig. 2. Four-year clinical outcomes in STEMI patients (n=334). A: total mortality. B: cardiac mortality. C: re-infarction. D: target vessel revascularization. E: 
stent thrombosis (definite+probable). F: major adverse cardiac events. STEMI: ST-elevation myocardial infarction, PES: Paclitaxel-eluting stent, SES: Sirolim-
us-eluting stent.
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stent thrombosis or TVR were the same between the SES and PES 
treated groups in 168 NSTEMI patients (Fig. 3). However, the occurr-
ence of MACE was significantly lower in the SES group {20.2±3.8% 
vs. 35.9±6.5%, hazard ratio (HR)=0.512, 95% CI=0.281-0.933, p= 
0.029} (Fig. 3F).
Four-year clinical outcomes in all patients (n=522) 
The occurrences of death (total and cardiac), recurrent infarction, 
or stent thrombosis were not different between the two groups, in-
cluding all 522 AMI patients (Fig. 4). However, the occurrence of 
TVR was significantly lower in the SES compared to the PES group 
(4.0±1.2% vs. 10.0±3.0%, HR=0.498, 95% CI=0.257-0.967, p=0.039) 
(Fig. 4D). The occurrence of MACE was also significantly lower in 
the SES group (19.4±2.5% vs. 29.4±3.5%, HR=0.645, 95% CI= 
0.443-0.940, p=0.021) (Fig. 4F).
Predictor of clinical outcomes
On multivariate analysis, all clinical and angiographic variables 
with p<0.2 in the univariate analysis and all clinically relevant pre-
dictors were tested: age, sex, diabetes, cardiogenic shock, multives-
sel disease, left main stem as the infarct related artery, pre-proce-
dural TIMI 2/3 flow, post-procedural minimal lumen diameter, stent 
type, type of myocardial infarction, and the duration of dual antipla-
telet therapy were tested. Independent predictors of 4-year MACE 
were age (HR: 1.026, 95% CI: 1.007 to 1.044, p=0.006) and diabetes 
mellitus (HR: 1.838, 95% CI: 1.170 to 2.886, p=0.006).
Fig. 3. Four-year clinical outcomes in NSTEMI patients (n=188). A: total mortality. B: cardiac mortality. C: re-infarction. D: target vessel revascularization. E: 
stent thrombosis (definite+probable). F: major adverse cardiac events. NSTEMI: non-ST elevation myocardial infarction, PES: Paclitaxel-eluting stent, SES: 
Sirolimus-eluting stent.
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Discussion
This retrospective study compared four year clinical efficacy of 
SES and PES in patients with AMI who underwent PCI. The main 
findings of this study were: 1) Both SES and PES demonstrated a 
high procedural success rate and favorable clinical outcome, 2) In 
all AMI patients, the occurrence of TVR and MACE were significant-
ly higher in the PES group. The occurrence of total death, cardiac dea-
th, recurrent infarction, or stent thrombosis was the same. 
Introduction of DES in the field of coronary intervention has mar-
kedly reduced the occurrence of restenosis by reducing neointimal 
hyperplasia and it has demonstrated better clinical outcome for 
the last decade. In the early phase of the DES era many interven-
tionists hesitated to implant DES in highly thrombogenic situa-
tions such as AMI, because of stent thrombosis concerns. Based on 
the results of favorable clinical studies, SES and PES have since been 
widely used in AMI patients.
5-7)10) However, there is limited long-
term clinical data directly comparing SES and PES in AMI. 
Although there have been several studies which reported that SES 
was superior to PES in terms of TVR,
4)10-12) no study has declared a 
superior long-term clinical efficacy of SES in terms of MACE. In our 
present study, however, the incidence of 4-year MACE as well as 
TVR was significantly lower in the SES group. It is hard to explain 
the statistical difference of MACE in this study even small sample 
size, the more difference of MACE after 2-year may partially explain 
this result.
Fig. 4. Four-year clinical outcomes in all patients (n=522). A: total mortality. B: cardiac mortality. C: re-infarction. D: target vessel revascularization. E: 
stent thrombosis (definite+probable). F: major adverse cardiac events. PES: Paclitaxel-eluting stent, SES: Sirolimus-eluting stent. 
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We found no significant difference in the rate of stent thrombo-
sis between the two DES groups (5.4±1.7% in the PES and 3.2±1.1% 
in the SES, p=0.53), which was comparable to or somewhat higher 
than previously reported rates (2.7-3.6% in the SES vs. 2.9-3.4% 
in the PES).
13)14) However, the PES group showed a trend towards 
the occurrence of stent thrombosis after one year, while the SES 
group showed a similar incidence. Since this study was not pro-
spectively designed and there was insufficient data about the use 
of antiplatelet therapy, this result remains to be established in a 
larger well designed study. 
The present study had some limitations. First, this study was 
based on retrospective, observational registry data. The baseline 
clinical characteristics were different: results may be influenced by 
these factors. Second, the number of evaluated patients was rela-
tively small and underpowered to detect the difference of clinical 
outcomes between the two groups. Third, this study was per-
formed in a single center. Fourth, PES use started later than SES 
use, because of late approval. However, the present study, as far as 
we are aware, is a valuable report comparing long-term safety and 
efficacy of SES and PES in patients presenting with AMI. A large 
number of studies with a more prolonged follow-up period and va-
riable types of new DES are needed to assess their safety and effi-
cacy profiles in AMI patients.
We concluded that among non-selected AMI patients who un-
derwent DES implantation, both SES and PES may be safe, but SES 
showed better four year clinical outcomes in terms of TVR and MACE.
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